Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by nozzpackon Nov 23, 2021 6:56pm
133 Views
Post# 34159367

RE:Epuris Sales in Mexico

RE:Epuris Sales in Mexico

Thank you.
Cph received a royalty on Mexican sales.
Italmax had revenues of $142 m US in 2920, so it has some heft.
Why Epuris continues to gain market share in Canada but not in the US is the price differential.

Epuris is the best product in its niche and when it is not brand price, it will lead the market, as is obvious in Canada.
I cannot find much info on the Mexican Epuris market, so its success there too will be price driven.

interesting statement from the Q3 CC..

" We are particularly excited about the opportunities in what is typically known as the legacy asset space.


We are evaluating a number of potential products and feel that asset values and cash flow dynamics are quite compelling."

<< Previous
Bullboard Posts
Next >>